88 related articles for article (PubMed ID: 28011980)
1. Potential safety concerns of TLR4 antagonism with irinotecan: a preclinical observational report.
Coller JK; Bowen JM; Ball IA; Wardill HR; van Sebille YZ; Stansborough RL; Lightwala Z; Wignall A; Shirren J; Secombe K; Gibson RJ
Cancer Chemother Pharmacol; 2017 Feb; 79(2):431-434. PubMed ID: 28011980
[TBL] [Abstract][Full Text] [Related]
2. Irinotecan-Induced Gastrointestinal Dysfunction and Pain Are Mediated by Common TLR4-Dependent Mechanisms.
Wardill HR; Gibson RJ; Van Sebille YZ; Secombe KR; Coller JK; White IA; Manavis J; Hutchinson MR; Staikopoulos V; Logan RM; Bowen JM
Mol Cancer Ther; 2016 Jun; 15(6):1376-86. PubMed ID: 27197307
[TBL] [Abstract][Full Text] [Related]
3. Establishment of a single-dose irinotecan model of gastrointestinal mucositis.
Gibson RJ; Bowen JM; Alvarez E; Finnie J; Keefe DM
Chemotherapy; 2007; 53(5):360-9. PubMed ID: 17713326
[TBL] [Abstract][Full Text] [Related]
4. Serum-derived bovine immunoglobulin/protein isolate in the alleviation of chemotherapy-induced mucositis.
Bateman E; Weaver E; Klein G; Wignall A; Wozniak B; Plews E; Mayo B; White I; Keefe D
Support Care Cancer; 2016 Jan; 24(1):377-385. PubMed ID: 26081596
[TBL] [Abstract][Full Text] [Related]
5. TLR4 deficiency upregulates TLR9 expression and enhances irinotecan-related intestinal mucositis and late-onset diarrhoea.
Wong DVT; Holanda RBF; Cajado AG; Bandeira AM; Pereira JFB; Amorim JO; Torres CS; Ferreira LMM; Lopes MHS; Oliveira RTG; Pereira AF; Sant'Ana RO; Arruda LM; Ribeiro-Júnior HL; Pinheiro RF; Almeida PRC; Carvalho RF; Chaves FF; Rocha-Filho DR; Cunha FQ; Lima-Júnior RCP
Br J Pharmacol; 2021 Oct; 178(20):4193-4209. PubMed ID: 34216140
[TBL] [Abstract][Full Text] [Related]
6. Palifermin reduces diarrhea and increases survival following irinotecan treatment in tumor-bearing DA rats.
Gibson RJ; Bowen JM; Keefe DM
Int J Cancer; 2005 Sep; 116(3):464-70. PubMed ID: 15800945
[TBL] [Abstract][Full Text] [Related]
7. Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis.
Logan RM; Gibson RJ; Bowen JM; Stringer AM; Sonis ST; Keefe DM
Cancer Chemother Pharmacol; 2008 Jun; 62(1):33-41. PubMed ID: 17703303
[TBL] [Abstract][Full Text] [Related]
8. Role of Toll-like receptor 4 in drug-drug interaction between paclitaxel and irinotecan in vitro.
Mallick P; Basu S; Moorthy B; Ghose R
Toxicol In Vitro; 2017 Jun; 41():75-82. PubMed ID: 28242239
[TBL] [Abstract][Full Text] [Related]
9. Single and combined supplementation of glutamine and n-3 polyunsaturated fatty acids on host tolerance and tumour response to 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin (CPT-11)/5-fluorouracil chemotherapy in rats bearing Ward colon tumour.
Xue H; Le Roy S; Sawyer MB; Field CJ; Dieleman LA; Baracos VE
Br J Nutr; 2009 Aug; 102(3):434-42. PubMed ID: 19250573
[TBL] [Abstract][Full Text] [Related]
10. Nutritional modulation of antitumor efficacy and diarrhea toxicity related to irinotecan chemotherapy in rats bearing the ward colon tumor.
Xue H; Sawyer MB; Field CJ; Dieleman LA; Baracos VE
Clin Cancer Res; 2007 Dec; 13(23):7146-54. PubMed ID: 18056195
[TBL] [Abstract][Full Text] [Related]
11. Effects of a novel toll-like receptor 4 antagonist IAXO-102 in a murine model of chemotherapy-induced gastrointestinal toxicity.
Tam JSY; Crame EE; Elz AS; Coller JK; Wignall A; Prestidge CA; Bowen JM
Cancer Chemother Pharmacol; 2022 Sep; 90(3):267-278. PubMed ID: 35962138
[TBL] [Abstract][Full Text] [Related]
12. Optimal antidiarrhea treatment for antitumor agent irinotecan hydrochloride (CPT-11)-induced delayed diarrhea.
Takasuna K; Hagiwara T; Watanabe K; Onose S; Yoshida S; Kumazawa E; Nagai E; Kamataki T
Cancer Chemother Pharmacol; 2006 Oct; 58(4):494-503. PubMed ID: 16437251
[TBL] [Abstract][Full Text] [Related]
13. High dosage of a fixed combination oxycodone/naloxone prolonged release: efficacy and tolerability in patients with chronic cancer pain.
Amato F; Ceniti S; Mameli S; Pisanu GM; Vellucci R; Palmieri V; Consoletti L; Magaldi D; Notaro P; Marcassa C
Support Care Cancer; 2017 Oct; 25(10):3051-3058. PubMed ID: 28470370
[TBL] [Abstract][Full Text] [Related]
14. Interleukin 15 offers selective protection from irinotecan-induced intestinal toxicity in a preclinical animal model.
Cao S; Black JD; Troutt AB; Rustum YM
Cancer Res; 1998 Aug; 58(15):3270-4. PubMed ID: 9699654
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy-induced gut toxicity and pain: involvement of TLRs.
Gibson RJ; Coller JK; Wardill HR; Hutchinson MR; Smid S; Bowen JM
Support Care Cancer; 2016 May; 24(5):2251-2258. PubMed ID: 26581898
[TBL] [Abstract][Full Text] [Related]
16. Novel Toll-like receptor-4 antagonist (+)-naloxone protects mice from inflammation-induced preterm birth.
Chin PY; Dorian CL; Hutchinson MR; Olson DM; Rice KC; Moldenhauer LM; Robertson SA
Sci Rep; 2016 Nov; 6():36112. PubMed ID: 27819333
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure. CPT-11 F205, F220, F221 and V222 study groups.
Freyer G; Rougier P; Bugat R; Droz JP; Marty M; Bleiberg H; Mignard D; Awad L; Herait P; Culine S; Trillet-Lenoir V
Br J Cancer; 2000 Aug; 83(4):431-7. PubMed ID: 10945486
[TBL] [Abstract][Full Text] [Related]
18. Irinotecan changes gene expression in the small intestine of the rat with breast cancer.
Bowen JM; Gibson RJ; Cummins AG; Tyskin A; Keefe DM
Cancer Chemother Pharmacol; 2007 Feb; 59(3):337-48. PubMed ID: 16799812
[TBL] [Abstract][Full Text] [Related]
19. The modulation of irinotecan-induced diarrhoea and pharmacokinetics by three different classes of pharmacologic agents.
Chowbay B; Sharma A; Zhou QY; Cheung YB; Lee EJ
Oncol Rep; 2003; 10(3):745-51. PubMed ID: 12684653
[TBL] [Abstract][Full Text] [Related]
20. The Effects of the Toll-Like Receptor 4 Antagonist, Ibudilast, on Sevoflurane's Minimum Alveolar Concentration and the Delayed Remifentanil-Induced Increase in the Minimum Alveolar Concentration in Rats.
Ruiz-Pérez D; Benito J; Polo G; Largo C; Aguado D; Sanz L; Gómez de Segura IA
Anesth Analg; 2016 May; 122(5):1370-6. PubMed ID: 26859874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
